Human Bioequivalence Test of Liraglutide Injection

NCT05029076 · Completed

Last updated 2026-05-28

This clinical trial tested whether a new version of the diabetes drug liraglutide works the same way in the body as the original version in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 28 people

Who can join Ages 18–60 · all sexes Healthy volunteers accepted.

Timeline Started 2019-05 · est. completion 2019-07

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05029076 ↗

Description as written by the study sponsor.

To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so as to provide reference for clinical evaluation and clinical medication;To observe the safety of the test preparation liraglutide injection and the reference preparation Victoza ® in healthy subjects.

Treatments tested

Liraglutide injection Drug

Human glucagon-like peptides-1 analogue
Victoza Drug

Human glucagon-like peptides-1 analogue

Main thing measured	Maximum (peak) plasma drug concentration(Cmax)
Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05029076 ↗